AbbVie Reports Full-Year and Fourth-Quarter 2024 Financial Results

Reports Full-Year Diluted EPS of $2.39 on a GAAP Basis, a Decrease of 12.1 Percent; Adjusted Diluted EPS of$10.12, a Decrease of 8.9 Percent; These Results Include an Unfavorable Impact of 1.52 Per Share Related to 2024 Acquired IPR&D and Milestones Expense  Delivers Full-Year Net Revenues of 56.334 Billion, an Increase of 3.7 Percent on a Reported Basis and 4.6 Percent on an Operational Basis   Full-Year Global Net Revenues from the Immunology Portfolio Were $26.682 Billion, an Increase of 2.1 Percent ...